---
title: "Haisen Pharm: Net profit of 60.7942 million yuan in the first half of 2025, a year-on-year increase of 4.74%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253017908.md"
description: "Haisen Pharm announced that in the first half of 2025, operating income was 242 million yuan, a year-on-year increase of 14.93%; net profit was 60.7942 million yuan, a year-on-year increase of 4.74%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital"
datetime: "2025-08-14T10:42:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253017908.md)
  - [en](https://longbridge.com/en/news/253017908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253017908.md)
generator: "portal-rs"
---

# Haisen Pharm: Net profit of 60.7942 million yuan in the first half of 2025, a year-on-year increase of 4.74%

Haisen Pharm announced that in the first half of 2025, operating revenue was 242 million yuan, a year-on-year increase of 14.93%; net profit was 60.7942 million yuan, a year-on-year increase of 4.74%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

### Related Stocks

- [001367.CN](https://longbridge.com/en/quote/001367.CN.md)

## Related News & Research

- [Trump’s Bond Buyback Push Puts Kevin Warsh in a Tough Spot — Peter Schiff Says Treasury ‘Pulled the Rug Out From Under’](https://longbridge.com/en/news/296615127.md)
- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [Scott Bessent Brings His Hedge Fund Playbook To Treasury. The Bond Market Is Fighting Back](https://longbridge.com/en/news/296520391.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [The rise in interest rates hit a 'raw nerve' at the White House. Bessent's plan has analysts on edge.](https://longbridge.com/en/news/296517751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**